US equities |
NVDA $242.62 ▲+1.56% SPCX $173.34 ▲+1.32% MU $1,060.61 ▼-0.32% AMD $636.59 ▲+0.77% META $743.59 ▲+0.23% MRVL $278.89 ▲+2.82% SNDK $1,704.15 ▼-0.00% AMZN $251.38 ▼-0.01%
FinancialContent

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

12.44 +0.02 (+0.12%)
Delayed Quote Updated: 9:30 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
What to Know About This Fund's $10 Million Bet on Gold Miners ↗
ASA Gold and Precious Metals Limited targets global mining equities, specializing in gold, silver, and other precious minerals investments. 
Via The Motley Fool
Topics Economy
News headline image
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
From Design Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller ↗
Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns. 
Via Benzinga
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >